• EI
  • Scopus
  • 食品科学与工程领域高质量科技期刊分级目录第一方阵T1
  • DOAJ
  • EBSCO
  • 北大核心期刊
  • 中国核心学术期刊RCCSE
  • JST China
  • FSTA
  • 中国精品科技期刊
  • 中国农林核心期刊
  • CA
  • WJCI
  • 中国科技核心期刊CSTPCD
  • 中国生物医学SinoMed
中国精品科技期刊2020
常悦,吴悦,郭建峰,等. 杨树桑黄多糖对糖尿病大鼠的降血糖效果及心肌保护作用[J]. 食品工业科技,2025,46(2):1−9. doi: 10.13386/j.issn1002-0306.2024020037.
引用本文: 常悦,吴悦,郭建峰,等. 杨树桑黄多糖对糖尿病大鼠的降血糖效果及心肌保护作用[J]. 食品工业科技,2025,46(2):1−9. doi: 10.13386/j.issn1002-0306.2024020037.
CHANG Yue, WU Yue, GUO Jianfeng, et al. Hypoglycemic Effects and Myocardial Protection of Sanghuangporus vaninii Polysaccharide on Diabetes Rats[J]. Science and Technology of Food Industry, 2025, 46(2): 1−9. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2024020037.
Citation: CHANG Yue, WU Yue, GUO Jianfeng, et al. Hypoglycemic Effects and Myocardial Protection of Sanghuangporus vaninii Polysaccharide on Diabetes Rats[J]. Science and Technology of Food Industry, 2025, 46(2): 1−9. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2024020037.

杨树桑黄多糖对糖尿病大鼠的降血糖效果及心肌保护作用

Hypoglycemic Effects and Myocardial Protection of Sanghuangporus vaninii Polysaccharide on Diabetes Rats

  • 摘要: 为探究杨树桑黄多糖(SP)对II型糖尿病大鼠降血糖效果及心肌保护作用,本文采用高糖高脂饲喂联合链脲佐菌素(STZ)诱导构建2型糖尿病(T2DM)大鼠模型,随机分为模型组(DM)、阳性对照组(MET)、低中高剂量杨树桑黄多糖组(SPL、SPM、SPH),以及正常组(CN),共六组进行饲养。4周灌胃连续干预后测定并记录大鼠的体重数据及多项生理生化指标,并对大鼠的胰腺及心肌组织进行病理学观察。结果表明,SP各剂量组与DM组相比均可改善T2DM大鼠体重下降,并可以显著降低空腹血糖值及血清胰岛素水平,改善其葡萄糖耐量(P<0.01或P<0.05)。SP组随着多糖剂量的增加,降低了血清总胆固醇(TC)、甘油三酯(TG)和低密度脂蛋白胆固醇(LDL-C)水平(P<0.01或P<0.05),高密度脂蛋白胆固醇(HDL-C)无明显变化;心肌酶乳酸脱氢酶(LDH)活力下降极显著(P<0.01);上调了总超氧化物歧化酶(SOD)和过氧化氢酶(CAT)活性(P<0.01或P<0.05),极显著下调了丙二醛(MDA)含量(P<0.01)。同时,SPM和SPH组降低了大鼠心肌组织中白介素-1β(IL-1β)和白介素-6(IL-6)的含量。HE染色结果表明:与DM组相比SP各组的胰岛细胞数目明显增加,细胞更加完整;经SP干预后与DM组相比,心肌组织细胞间隙均匀,空泡化减少,其中SPH组改善效果最明显。综上所述,杨树桑黄多糖具有保护T2DM大鼠胰腺和心脏组织结构、调节血糖水平、降低血脂、减轻胰岛素抵抗等抗糖尿病作用。

     

    Abstract: To examine the hypoglycemic effects and myocardial protection of Sanghuangporus vaninii polysaccharide (SP) in T2DM rats, these effects were assessed in rats fed a high glucose and high fat diet combined with streptozotocin (STZ). The rats were randomly assigned to one of the following six groups: the diabetes mellitus (DM), metformin (MET), low-, medium-, and high-dose SP (SPL, SPM, and SPH), and control (CN) groups. Following 4 weeks of continuous intervention by gavage, the weights and multiple physiological and biochemical indicators of rats were measured and recorded, and we performed pathological observations of the pancreatic and myocardial tissues of rats.The results revealed that SP at all assessed doses can reduce weight loss in T2DM rats compared to the DM group, significantly reduce fasting blood glucose and serum insulin levels, and improve glucose tolerance (P<0.01 or P<0.05). With an increase in the dosage of SP, in serum total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) levels in the SP-fed rats (P<0.01 or P<0.05), whereas no significant changes in high-density lipoprotein cholesterol (HDL-C). Furthermore, there was a significant reduction in lactate dehydrogenase (LDH) activity (P<0.01), an upregulation of total superoxide dismutase (SOD) and catalase (CAT) activities (P<0.01 or P<0.05), and a significant reduction in malondialdehyde (MDA) content (P<0.01). Additionally, the SPM and SPH treatments reduced the levels of interleukin-1β (IL-1β) in rat myocardial tissues and the contents of interleukin-6 (IL-6). HE staining revealed a significant increase in the number of pancreatic islet cells in SP group rats than in the DM group rats, and the cells were more complete. Compared with the DM group, the myocardial tissue showed uniform cell gaps and reduced vacuolization after SP intervention, with the SPH group exhibiting the most significant improvement. In summary, SP can protect the structure of pancreatic and cardiac tissues, regulate blood sugar levels, reduce blood lipid contents, reduce insulin resistance, and have anti-diabetic effects in T2DM rats.

     

/

返回文章
返回